Preparing your space
Your library and workspace are being arranged now.
Preparing your space
Your library and workspace are being arranged now.
Loading the business overview…
Explore the research to see how business evidence informs assumptions and valuation.
Start with the business evidence, then follow the assumptions through to scenarios and valuation.
Valuation and assumptionsWritten at USD 207.8500; now USD 200.14000000 (-4%). Upside to the weighted case has moved from -4% to -0%.
Danaher Corporation is a wide-moat compounder - a portfolio of bioprocessing, life-science and diagnostic franchises run through a codified operating system - whose economics are driven primarily by the pace of biopharmaceutical manufacturing capacity investment, the operating leverage that volume produces on a cost base deliberately retained through the downturn, and the returns earned on the roughly $47bn of acquisitions deployed since 2020. Its principal competitive advantage is regulatory switching cost: once a chromatography resin or filtration medium is written into an approved drug's manufacturing filing, it cannot be changed without re-validation, which annuitises the consumable stream for the drug's commercial life and is why the Biotechnology segment earns a 25.6% operating margin. Its most important vulnerabilities are a bioprocessing recovery that has now been deferred three years running, a Masimo acquisition bought at 18x forward EBITDA that will not earn its cost of capital before about 2031, leverage at roughly 2.8x that gates the acquisition engine for two years, and a CEO transition on 1 October 2026 in a company whose premium rests on culture. Under the base case - core revenue growth recovering to 5%, adjusted operating margin rebuilding from 27.1% toward 29-30%, free cash flow compounding at 7% a year to $7.7bn by 2031, discounted at an 8.0% weighted average cost of capital with 3.5% terminal growth, plus $21 per share for the acquisition capability - intrinsic value is approximately $200 per share versus a market price of $207.85. The investment therefore depends primarily on whether mid-teens bioprocessing order growth converts into mid-single-digit core revenue growth and holds there, because at 2-3% core growth the shares are worth $150 and at 6-7% they are worth $250. The most important evidence to monitor is bioprocessing book-to-bill, core revenue growth excluding respiratory testing, adjusted operating margin, and the 2027 guidance the incoming chief executive sets in January.
| Item | Value |
|---|---|
| Company | Danaher Corporation |
| Ticker / exchange | DHR / NYSE |
| Share price | $207.85 (4 September 2026) [S9] |
| Market capitalization | ~$146bn [S9] |
| Enterprise value | ~$169bn [S10] |
| Industry | Life sciences tools, bioprocessing and diagnostics |
| Primary geographies | North America ~40%, Europe ~30%, high-growth markets including China ~25% [Unverified — approximate mix] |
| Investment classification | Compounder |
| Business quality | High |
| Competitive advantage | Strong |
| Financial quality | Strong |
| Growth outlook | Moderate — core growth was 2.0% in H1 2026; management expects to exit the year at mid-single digits [S1] |
| Balance-sheet risk | Low-to-Medium — leverage rose to roughly 2.8× net debt/EBITDA on the Masimo acquisition [Est.] |
| Valuation attractiveness | Fair |
| Overall risk | Medium |
| Base-case intrinsic value | $200 |
| Bull-case intrinsic value | $285 |
| Bear-case intrinsic value | $115 |
| Probability-weighted value | $200 → −4% versus $207.85 |
| Expected annualized return, base case | +7% to +8% over three to five years |
| Investment stance | Hold |
Thesis in five bullets
Regulatory switching costs in bioprocessing — the core of the moat, and it is a strong one. What creates it: a biologic's manufacturing process, including the specific chromatography resin, filtration media and single-use assemblies, is described in the regulatory filing. Changing a supplier on a commercial product requires re-validation, comparability studies and a regulatory submission — cost and, more importantly, risk to supply of an approved medicine. Economic value: the consumable stream attached to an approved drug is annuitised for the product's commercial life, with low-single-digit annual price. Evidence: Biotechnology's 25.6% segment operating margin [S3]; the fact that mid-teens order growth persisted through a period when customers were actively cutting spend [S5]; and the absence of price competition through the 2023–24 destocking. Replicable? Only prospectively, at process development, for new molecules. Durability: very high — measured in the commercial life of drugs, i.e. a decade or more. What weakens it: a shift in modality (cell and gene therapy, or fully continuous processing) that resets supplier choice for a new generation of products; and second-sourcing mandates after the COVID-era supply shocks.
Installed base and razor/blade in diagnostics — moderate. Analysers placed in hospital laboratories pull reagent and consumable revenue for 7–10 years, with LIS integration and workflow validation adding friction. Evidence: Diagnostics' 26.7% FY2025 margin [S3] on a business facing Chinese procurement pressure. Weakness: the buyer is a hospital system under reimbursement pressure, and analyser placements are competitively tendered. Masimo strengthens this with a large hospital installed base in patient monitoring.
The Danaher Business System — real, and the hardest advantage to price. What creates it: a codified operating system applied to every acquisition. Economic value: it is why Danaher can pay 18× forward EBITDA for Masimo [S6] and expect to earn a return — the model is to buy good assets at full prices and improve growth and margin. Evidence: the Diagnostics platform grew from roughly $6.0bn of revenue in 2017 to $11.0bn today with operating profit approximately tripling, under the executive who becomes CEO on 1 October 2026 [S8]. That is a specific, checkable, and impressive datapoint. Replicable? Many have tried; few have sustained it. What weakens it: scale. DBS improvements on a $9.8bn acquisition move the group less than they did on a $1bn one, and the pool of assets large enough to matter is shrinking.
Scale and R&D. $1.6bn of annual R&D [S14], 6.5% of revenue, spread across three platforms. Meaningful but not a moat on its own.
Brand. Strong at the operating-company level (Cytiva, Cepheid, Beckman, Leica, SCIEX) and essentially irrelevant at the Danaher level.
Absent: network effects, data advantage of consequence, cost advantage (Danaher is a premium-price supplier), geographic density.
Quantitative tests:
Moat rating: WIDE, on the operating businesses. The regulatory lock-in in bioprocessing is among the most durable switching-cost mechanisms in industry, and it is paired with a diagnostics installed base and a genuine operating system. The qualification is that the moat protects the businesses, not necessarily the returns to Danaher shareholders, because the price paid for those businesses has risen to the point where the moat's excess returns are largely capitalised into the acquisition multiple.
| Risk | Prob. | Impact | Horizon | Leading indicator | Mitigants | Priced in? |
|---|---|---|---|---|---|---|
| Bioprocessing recovery is pushed out again | 50% | Core growth stays 2–3%; the margin recovery does not arrive; the shares de-rate toward 18–20× | 2026–28 | Order growth versus revenue conversion; resin shipment timing | Mid-teens order growth [S5]; regulatory lock-in means demand is deferred, not lost | Partly — analysts cut targets after Q2 [S9] |
| Masimo underperforms or distracts | 35% | ~$0.30–0.50 of EPS versus plan; $9.8bn of capital earning below WACC | 2027–31 | Diagnostics segment margin; any separate Masimo commentary | DBS track record; a large hospital installed base | No |
| CEO transition disrupts the DBS operating cadence | 20% | Slow, cumulative, hard to detect early | 2027–29 | Core growth and margin execution versus guidance in 2027 | A nine-year internal appointment with a strong platform record [S8] | No |
| China procurement pressure returns | 30% | ~100bp of group core growth | 1–3 yrs | Provincial VBP tenders | Headwinds already fading [S4] | Partly |
| Academic and NIH funding contracts further | 35% | Life Sciences core growth | 1–3 yrs | Grant appropriations | Segment already at its trough | Partly |
| Modality shift resets bioprocessing supplier choice | 10% | Erodes the core moat over a decade | 5–10 yrs | New-molecule process development wins | Danaher is present in the new modalities | No |
| Risk | Prob. | Impact | Priced in? |
|---|---|---|---|
| Leverage at ~2.8× constrains M&A for two years | ~80% | Removes ~100bp/yr of acquired revenue growth | No |
| Rising rates on refinancing | 25% | Modest — debt is long-dated and fixed at 1.65–4.00% [S2] | Yes |
| Distress or covenant breach | <1% | $5.3bn of free cash flow, $10bn of undrawn facilities [S2] | n/a |
| Dilution | ~0% | Share count is falling | n/a |
| Risk | Prob. | Impact | Priced in? |
|---|---|---|---|
| The price already requires ~8%/yr free-cash-flow growth against −0.6%/yr realised over 2020–25 [Est., §22] | — | A de-rate to 20× forward earnings is −16% | No — this is the principal risk in the shares |
| Multiple compression from 23.9× forward toward the sector | 40% | −10% to −20% | No |
| Quality premium erodes if core growth stays at 2% | 35% | The compounder framing depends on compounding | No |
Tail risks. A product-quality or regulatory failure at a bioprocessing site, which would be doubly damaging because supply security is the product. A major litigation or FCPA event. A Chinese restriction on Western diagnostic equipment. A step change in biologic manufacturing technology. All are low probability; none is priced.
| Input | Value |
|---|---|
| Risk-free rate | 4.79% (10-yr UST, 2 Sep 2026) [S13] |
| Equity risk premium | 5.0% (assumption) |
| Beta | 0.81 [S10] |
| Cost of equity | 8.84% |
| Pre-tax cost of debt | ~3.8% blended [Est. from S2: EUR 3.25–4.00%, CHF 1.65–2.51%, legacy USD paper] |
| After-tax cost of debt | 2.96% |
| Debt weight (market values) | 15.4% ($26.56bn of $172.7bn) |
| WACC | 8.0% (sensitivity at 7.5% and 8.5%) |
| Terminal growth | 3.5% |
| Tax rate | 22% |
| Diluted share count | 703m today, ~690m by 2031 on continued buybacks [S10][S14] |
| Stock-based compensation | Expensed — $151m pretax in H1 2026 [S2], charged in both GAAP and adjusted figures and in all valuations here |
Three tensions in my own forecast, stated rather than resolved:
Assumptions: FY2026 free cash flow $5.5bn [Est., H1 $2.35bn with a seasonally stronger H2]; growing 7% a year on 5% core revenue growth plus margin leverage, net of rising cash taxes; no incremental acquisition spend and no acquired growth.
| $bn | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|
| Free cash flow | 5.89 | 6.30 | 6.74 | 7.21 | 7.72 |
| Discount factor at 8.0% | 1.080 | 1.166 | 1.260 | 1.360 | 1.469 |
| Present value | 5.45 | 5.40 | 5.35 | 5.30 | 5.25 |
| Bridge ($bn) | 7.5% WACC / 4.0% g | 8.0% / 3.5% | 8.5% / 3.0% |
|---|---|---|---|
| PV of 2027–2031 free cash flow | 27.3 | 26.75 | 26.2 |
| Terminal multiple on 2031 FCF | 25.9× | 23.0× | 20.7× |
| PV of terminal value | 139.3 | 120.9 | 106.3 |
| Plus H2 2026 free cash flow | 3.2 | 3.2 | 3.2 |
| Enterprise value | 165.8 | 147.1 | 132.1 |
| Less net debt | (22.2) | (22.2) | (22.2) |
| Equity value | 143.6 | 124.9 | 109.9 |
| ÷ 703m shares | $204 | $178 | $156 |
| Plus DBS / acquisition capability | +$20 | +$21 | +$20 |
| Intrinsic value per share | $224 | $199 | $176 |
Base-case intrinsic value: $176–$224, midpoint $200.
The $21 per share attributed to the acquisition capability is roughly $15bn, and represents the present value of Danaher deploying ~$3bn a year at a modest premium to its cost of capital under DBS. It is a judgement, not a calculation. Set it to zero and the base case is $178; double it and the base case is $220.
Set out in §22: the price requires roughly 8% annual free-cash-flow growth, implying 5.5–6.0% core revenue growth and ~30% adjusted operating margin by 2031 — against 2.0% core growth in H1 2026 and 27.1% margin today, and against realised free-cash-flow growth of −0.6% a year over 2020–2025 [Est., S14].
| Metric | Danaher | Thermo Fisher [S12] | Comment |
|---|---|---|---|
| Forward P/E | 23.9× [S9] | 23.6× | Essentially identical to its closest peer |
| Trailing P/E (GAAP) | 37.6× [S9] | — | Distorted by intangible amortisation |
| EV/EBITDA | 21.1× [S10] | 22.8× | A modest discount to Thermo |
| EV/Sales | 6.8× [S10] | 5.8× | A premium, justified by 58.8% gross margin versus 41.0% |
| P/FCF | 26.8× [S10] | — | ~3.7% free-cash-flow yield |
| PEG | 2.61 [S10] | — | Expensive on growth-adjusted terms |
| Dividend yield | 0.78% [S10] | 0.31% | Immaterial to the return in both cases |
| ROIC | 6.4% [S10] | 8.8% [S12] | Danaher's is more depressed by acquisition goodwill |
Should Danaher trade at a premium or a discount? A premium to the tools sector is warranted: a 58.8% gross margin against Thermo's 41.0%, the strongest switching-cost position in bioprocessing, and DBS. A discount to its own history is also warranted: core growth of 2% versus a decade-long mid-single-digit average, leverage at 2.8× versus a historical 1.5–2×, a CEO transition, and $47bn of recent acquisitions whose returns are unproven. At 23.9× forward earnings — the same multiple as Thermo Fisher, and below its own 25–30× history — the market has already made both adjustments. That is a fair outcome, not a cheap one.
Sum of the parts [Est.], on FY2025 segment profit and peer-appropriate multiples:
| Segment | Operating profit | Multiple | Value |
|---|---|---|---|
| Biotechnology | $1.86bn | 22× EBIT (best-in-class moat, cyclical recovery) | $41bn |
| Diagnostics (incl. Masimo) | $2.65bn + ~$0.35bn | 18× EBIT | $54bn |
| Life Sciences | $0.52bn GAAP, ~$1.30bn ex-amortisation [Est.] | 17× EBIT | $22bn |
| Corporate | ($0.35bn) | 15× | ($5bn) |
| Enterprise value | $112bn | ||
| Less net debt | ($22bn) | ||
| Equity | $90bn = $128/share |
The sum of the parts is far below the DCF because multiples capitalise current, cyclically depressed profit while the DCF capitalises a recovery. The gap between $128 and $200 is precisely the value of the margin and volume recovery, and it is the single largest judgement in this report.
Earnings-power value — normalised owner earnings of $5.70–$6.40 per share (§10) at a 6.5% required yield: $88–$98 per share, plus recovery value. This no-growth figure is close to the bear case and is the right reconciliation.
Replacement value: not meaningful. Cytiva's regulatory position in approved filings cannot be replaced at any price.
Book value of $52.59bn, or $75 per share [S14], is over half goodwill and intangibles and is not a floor.
Trigger: the repeated deferral of large resin shipments is not timing but a slower structural pace of biologics capacity investment. Biotech funding stays tight, pharma cost programmes extend, and academic funding contracts further.
Operating mechanism: bioprocessing orders normalise from mid-teens to mid-single digits as the order book proves to have contained pull-forward. Core growth settles at 2–3%. With volume flat, the 40–45% incremental margin never engages and adjusted operating margin stays near 27%. Leverage at 2.8× keeps the M&A engine idle through 2028, removing the ~100bp a year of acquired growth the algorithm assumes. Masimo delivers its cost synergies but not its revenue growth, and $9.8bn earns roughly 5%. The new CEO, inheriting a slow-growth company, prioritises margin over investment.
Financial consequence: revenue grows ~3% a year to $30bn by 2031; adjusted EPS reaches roughly $9.30 by 2029; free cash flow grows ~3% a year to $6.1bn.
Valuation consequence: the compounder premium is withdrawn. At an 8.5% discount rate and 2.5% terminal growth — a 17× terminal multiple — enterprise value is roughly $93bn, equity $71bn, and the acquisition capability is worth nothing. Intrinsic value: $115 per share.
Trigger: mid-teens bioprocessing order growth converts to revenue as customer capacity comes online through 2027; the deferred $100m+ of resin lands; respiratory testing finishes shrinking; China stabilises.
Operating mechanism: core growth reaches 5–6% and holds. Volume flows through the retained cost base at 40–45% incremental margins, lifting adjusted operating margin from 27.1% toward 29–30% by 2029. Life Sciences continues the recovery evident in Q2 2026 (+5.5% core, Pall applied filtration +10%, Abcam's best quarter since acquisition [S5]). Masimo is integrated, delivers its $175m of synergies and contributes ~$0.50 of EPS by 2029. Free cash flow of $5.5–7.7bn a year deleverages the balance sheet to ~2× by 2028, and bolt-on M&A resumes at $2–3bn a year. Buybacks continue at roughly 1% of shares annually.
Financial consequence: revenue reaches roughly $33bn by 2031; adjusted EPS about $11.00 in 2029 and $13.10 in 2031; free cash flow $7.7bn in 2031.
Valuation consequence: discounted at 8.0% with 3.5% terminal growth, plus $21 per share for the acquisition capability, intrinsic value: $200 per share (range $176–$224).
Trigger: GLP-1 and antibody manufacturing capacity, cell and gene therapy commercialisation, and biosecurity-driven onshoring of biologics production combine into a multi-year capital cycle of the kind last seen in 2020–21. China normalises fully and academic funding recovers.
Operating mechanism: Biotechnology core growth reaches low double digits and Life Sciences instruments enter a replacement cycle; group core growth reaches 7–8%. On a cost base sized for less, adjusted operating margin returns to 31%. Masimo exceeds its synergy plan and DBS lifts its growth into the high single digits, validating the acquisition and the Diagnostics platform's expansion into patient monitoring. Deleveraging is rapid and Danaher resumes large-scale M&A from 2028 at attractive prices in a still-fragmented market.
Financial consequence: revenue approaches $38bn by 2031; adjusted EPS around $12.60 in 2029; free cash flow $9.4bn in 2031.
Valuation consequence: at a 7.5% discount rate with 4.0% terminal growth, plus $30 per share for a demonstrably working acquisition engine, intrinsic value: $285 per share.
| Case | Value | Prob. | Contribution | Versus $207.85 |
|---|---|---|---|---|
| Bear | $115 | 25% | $28.75 | −45% |
| Base | $200 | 50% | $100.00 | −4% |
| Bull | $285 | 25% | $71.25 | +37% |
| Weighted | $200 | 100% | −4% |
The probabilities sum to 1.00, and unlike a more speculative security that is appropriate here. Danaher's outcome distribution is genuinely bounded: the businesses are durable, the balance sheet cannot fail, and the range of plausible 2031 free cash flow spans roughly $6bn to $9bn rather than an order of magnitude. Where the evidence is thin — the terminal growth rate, and the return on $47bn of acquisitions — I have widened the discount-rate and terminal-growth range rather than pretending to a point estimate.
Downside to the probability-weighted value: −4%. The shares are fairly valued.
| Dimension | Score |
|---|---|
| Business quality | 8/10 |
| Competitive advantage | 8/10 |
| Management and capital allocation | 8/10 |
| Financial strength | 7/10 |
| Growth prospects | 6/10 |
| Valuation attractiveness | 5/10 |
| Risk/reward | 6/10 |
| Overall investment quality | 7/10 |
1. Is this a good business? Yes — genuinely and durably. A 58.8% gross margin, roughly 21% free-cash-flow margins, low capital intensity, high recurring revenue, and the strongest switching-cost mechanism in life sciences: a consumable written into a drug's regulatory filing cannot be changed without re-validation.
2. Is it becoming stronger or weaker? Operationally, weaker for three years and now inflecting: core growth of 2.0% in H1 2026 with orders growing mid-teens [S1][S5]. Structurally, unchanged — no share has been lost and no price competition has emerged. Financially, modestly weaker: leverage rose from ~1.5× to ~2.8× on Masimo [Est.], which will gate M&A for about two years.
3. Does it possess a durable competitive advantage? Yes — wide. Regulatory switching costs in bioprocessing, a diagnostics installed base, and the Danaher Business System. The qualification is that the moat protects the businesses more reliably than it protects shareholder returns, because the prices paid to acquire those businesses have capitalised much of the excess return.
4. The three most important drivers of future value: Biotechnology (bioprocessing) core growth (±100bp sustained ≈ ±$14/share); group adjusted operating margin (±100bp ≈ ±$6.50/share); and the return earned on acquisition capital, of which Masimo at 18× forward EBITDA is the current test.
5. The three largest risks: that the bioprocessing recovery is deferred a fourth time and core growth settles at 2–3%; that $47bn of acquisitions since 2020 earns roughly its cost of capital rather than more; and valuation — the price already requires management's plan to work.
6. The most important dependency: the pace of biopharmaceutical manufacturing capacity investment. Everything else is second order.
7. What the market appears to be pricing in: approximately 8% annual free-cash-flow growth, implying 5.5–6.0% core revenue growth and ~30% adjusted operating margin by 2031 [Est.] — against 2.0% core growth in H1 2026, full-year guidance of 3–4% cut from 3–6%, and realised free-cash-flow growth of −0.6% a year over 2020–2025.
8. Where could the market be wrong? In Danaher's favour: if this is a genuine multi-year biologics capacity cycle, 2% core growth is the wrong anchor and the shares are worth closer to $285. Against Danaher: if mid-teens order growth proves to contain pull-forward, or if Masimo repeats Aldevron rather than Cytiva, the compounder premium is withdrawn and the shares are worth $115.
9. Fair intrinsic value: $200 per share base case, range $176–$224; probability-weighted across scenarios, also $200.
10. Margin of safety at today's price: Essentially none — approximately −4%. The shares are fairly valued, not mispriced in either direction.
11. Reasonable annualized return over 3–5 years: +7.6% a year in the base case over three years (+9.7% from fundamentals alone, before the assumed multiple compression); +6.5% probability-weighted over three years and +7.5% over five. That is at or slightly below the 8.8% cost of equity.
12. The single development that would most strengthen the thesis: bioprocessing book-to-bill holding above 1.0 for three consecutive quarters while Biotechnology core growth exceeds 8%. That would convert the order book from commentary into revenue and validate the entire margin-recovery arithmetic.
13. The single development that would most invalidate it: group core revenue growth below 3% for four consecutive quarters. At that rate the compounder premium is unwarranted regardless of business quality, and the fair value is roughly $150.
14. At what price does it become clearly attractive? Below $170 — a ~15% discount to the base case, at which the expected return rises above 11% a year and an investor is paid for the transition risk and the unproven acquisition returns rather than assuming both work.
15. What price would imply excessive optimism? Above $270 — near the bull case, which requires 7–8% core growth, 31% adjusted margins and a demonstrably working M&A engine to arrive together.
Danaher Corporation is a wide-moat compounder — a portfolio of bioprocessing, life-science and diagnostic franchises run through a codified operating system — whose economics are driven primarily by the pace of biopharmaceutical manufacturing capacity investment, the operating leverage that volume produces on a cost base deliberately retained through the downturn, and the returns earned on the roughly $47bn of acquisitions deployed since 2020. Its principal competitive advantage is regulatory switching cost: once a chromatography resin or filtration medium is written into an approved drug's manufacturing filing, it cannot be changed without re-validation, which annuitises the consumable stream for the drug's commercial life and is why the Biotechnology segment earns a 25.6% operating margin. Its most important vulnerabilities are a bioprocessing recovery that has now been deferred three years running, a Masimo acquisition bought at 18× forward EBITDA that will not earn its cost of capital before about 2031, leverage at roughly 2.8× that gates the acquisition engine for two years, and a CEO transition on 1 October 2026 in a company whose premium rests on culture. Under the base case — core revenue growth recovering to 5%, adjusted operating margin rebuilding from 27.1% toward 29–30%, free cash flow compounding at 7% a year to $7.7bn by 2031, discounted at an 8.0% weighted average cost of capital with 3.5% terminal growth, plus $21 per share for the acquisition capability — intrinsic value is approximately $200 per share versus a market price of $207.85. The investment therefore depends primarily on whether mid-teens bioprocessing order growth converts into mid-single-digit core revenue growth and holds there, because at 2–3% core growth the shares are worth $150 and at 6–7% they are worth $250. The most important evidence to monitor is bioprocessing book-to-bill, core revenue growth excluding respiratory testing, adjusted operating margin, and the 2027 guidance the incoming chief executive sets in January.
S1 — Danaher Reports Second Quarter 2026 Results. Danaher Corporation / PR Newswire. primary_press. Published 2026-07-21; read 2026-09-04.
https://www.prnewswire.com/news-releases/danaher-reports-second-quarter-2026-results-302830086.html
S2 — Form 10-Q for the quarter ended June 26, 2026 — Masimo acquisition note, debt note, segment note, share repurchases, stock compensation. Danaher Corporation. filing. Published 2026-07-21; read 2026-09-04.
https://filecache.investorroom.com/mr5ir_danaher/998/DHR%2010-Q%202026%207-21.pdf
S3 — Danaher Reports Fourth Quarter and Full Year 2025 Results. Danaher Corporation / PR Newswire. primary_press. Published 2026-01-28; read 2026-09-04.
https://www.prnewswire.com/news-releases/danaher-reports-fourth-quarter-and-full-year-2025-results-302671883.html
S4 — Danaher Corp (DHR) Q2 2026 Earnings Call Highlights. GuruFocus via Yahoo Finance. transcript summary. Published 2026-07-21; read 2026-09-04.
https://finance.yahoo.com/markets/stocks/articles/danaher-corp-dhr-q2-2026-190035240.html
S5 — DHR Q2 2026 Earnings Call: revenue grows 3%, EPS beats at $1.94, bioprocessing misses as $100M+ resin shipments slip to 2027. BigGo Finance. transcript summary. Published 2026-07-21; read 2026-09-04.
https://finance.biggo.com/news/US_DHR_2026-07-21
S6 — Danaher To Acquire Masimo Corporation. Danaher Corporation / PR Newswire. primary_press. Published 2026-02-17; read 2026-09-04.
https://www.prnewswire.com/news-releases/danaher-to-acquire-masimo-corporation-302689266.html
S7 — Danaher Completes Acquisition of Masimo Corporation. Danaher Corporation. primary_press. Published 2026-06-10; read 2026-09-04.
https://investors.danaher.com/2026-06-10-Danaher-Completes-Acquisition-of-Masimo-Corporation
S8 — Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer. Danaher Corporation. primary_press. Published 2026-08-03; read 2026-09-04.
https://investors.danaher.com/2026-08-03-Danaher-Appoints-Julie-Sawyer-Montgomery-as-President-and-Chief-Executive-Officer
S9 — DHR quote, valuation and analyst forecast. StockAnalysis.com. secondary. Accessed and read 2026-09-04.
https://stockanalysis.com/stocks/dhr/
S10 — DHR key statistics. StockAnalysis.com. secondary. Accessed and read 2026-09-04.
https://stockanalysis.com/stocks/dhr/statistics/
S11 — DHR analyst forecast and consensus estimates. StockAnalysis.com. secondary. Accessed and read 2026-09-04.
https://stockanalysis.com/stocks/dhr/forecast/
S12 — Thermo Fisher Scientific (TMO) key statistics. StockAnalysis.com. secondary. Accessed and read 2026-09-04.
https://stockanalysis.com/stocks/tmo/statistics/
S13 — H.15 Selected Interest Rates, data for September 2, 2026. Federal Reserve Board. regulator. Published 2026-09-03; read 2026-09-04.
https://www.federalreserve.gov/releases/h15/
S14 — SEC XBRL facts for Danaher Corporation as stored by the commissioning platform, covering FY2020–FY2025 and the six months ended 26 June 2026. filing (XBRL extraction). No URL. Read 2026-09-04. Note: the stored short-term debt fact carries a period end of 1 July 2011 and was not used; the current figure was taken from [S2].
Six things could not be established. (1) Any quantified tariff impact on 2026 earnings - neither accessible summary of the Q2 earnings call quantified it and the full transcript was not retrievable. (2) Segment-level adjusted operating margins, so the split between economic and amortisation-driven margin differences by segment is inferred rather than read. (3) The nature and size of the charge that produced Life Sciences' $239m segment operating loss in Q2 2025, which flatters the year-over-year comparison. (4) Post-Masimo credit rating actions. (5) The 2026 proxy, and therefore executive compensation structure, Rales family holdings and any related-party transactions. (6) Consensus estimates beyond FY2026 and the company's recurring-revenue percentage. Separately, the terminal growth rate and the $21 per share ascribed to the acquisition capability together account for roughly $150 of the $200 base case and cannot be defended with evidence from a company that has grown revenue 2.0% a year over five years; a reader who assumes 2.5% terminal growth should value the shares near $160.
These model scenarios depend on their inputs. Review the assumptions and supporting evidence alongside the implied values.
earnings multiple v2 · as of 2026-09-12
Sign in for the price chart, where every input traces back to a filing, an adjustable scenario sandbox, and companies that move with DHR.
Create a free account →